Exact Sciences Corporation is a global leader in cancer diagnostics and screening, focused on preventing, detecting, and treating cancer through innovative molecular diagnostic solutions. Founded in 1995 in Marlborough, Massachusetts, the company has grown to employ approximately 6,500 people and operates in over 120 countries. Its mission emphasizes early cancer detection and prevention, guided by core values of innovation, integrity, quality, teamwork, and accountability.
The company offers a diverse range of cancer diagnostic tests, including Cologuard®, a non-invasive stool DNA test for colorectal cancer, and the Oncotype DX Breast Recurrence Score® test for genomic assessment. Recent additions to their portfolio include the OncoExTra® cancer therapy selection test and a Multi-cancer Earlier Detection (MCED) test. Exact Sciences has expanded its capabilities through strategic acquisitions, enhancing its personalized cancer diagnostics and broadening its test offerings. Headquartered in Madison, Wisconsin, the company is committed to advancing cancer care and has been recognized as a Great Place To Work for seven consecutive years.
Quest Diagnostics Inc is a leading independent provider of diagnostic testing, information, and services in the us. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
Quest Diagnostics Inc is a leading independent provider of diagnostic testing, information, and services in the us. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
Mayo Clinic is a nonprofit organization committed to clinical practice, education, and research, providing whole-person care and solving complex medical challenges for patients from around the world.
Developer of a cloud-based electronic health record platform designed to connect doctors, patients and data to drive better health and save lives. The company's EHR is a comprehensive practice management software platform that includes charting, scheduling, billing, e-prescribing, lab integrations and secure messaging, enabling healthcare providers to manage their patient population and coordinate care.
23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment includes Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment.